<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3761">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03057951</url>
  </required_header>
  <id_info>
    <org_study_id>1245.110</org_study_id>
    <secondary_id>2016-002278-11</secondary_id>
    <nct_id>NCT03057951</nct_id>
  </id_info>
  <brief_title>EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)</brief_title>
  <official_title>A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate efficacy and safety of empagliflozin versus placebo on
      top of guideline-directed medical therapy in patients with heart failure with preserved
      ejection fraction
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite primary endpoint - Time to first event of adjudicated CV (Cardiovascular) death or adjudicated HHF (Hospitalisation for Heart Failure) in patients with Heart Failure with preserved Ejection Fraction (HFpEF)</measure>
    <time_frame>up to 38 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adjudicated HHF (Hospitalisation for Heart Failure) (first and recurrent)</measure>
    <time_frame>up to 38 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR (Estimated Glomerular Filtration Rate) (CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration Equation))cr slope of change from baseline</measure>
    <time_frame>up to 38 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of sustained reduction of eGFR</measure>
    <time_frame>up to 38 months</time_frame>
    <description>Time to first occurrence of sustained reduction of &gt;= 40% eGFR (CKD-EPI)cr or
sustained eGFR (CKD-EPI)cr &lt;15 mL/min/1.73 m2 for patients with baseline eGFR &gt;=30 mL/min/1.73 m2
sustained eGFR (CKD-EPI)cr &lt;10 mL/min/1.73 m2 for patients with baseline eGFR &lt;30 mL/min/1.73 m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first adjudicated HHF (Hospitalisation for Heart Failure)</measure>
    <time_frame>up to 38 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to adjudicated CV (Cardiovascular) death</measure>
    <time_frame>up to 38 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to all-cause mortality</measure>
    <time_frame>up to 38 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of DM (Diabetes Mellitus)</measure>
    <time_frame>up to 38 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in clinical summary score (HF (Chronic Heart Failure) symptoms and physical limitations domains) of the Kansas City Cardiomyopathy Questionnaire (KCCQ) at week 52</measure>
    <time_frame>Baseline and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of all-cause hospitalisation (first and recurrent)</measure>
    <time_frame>up to 38 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4126</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <arm_group_label>Empagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male or female patient, age &gt;= 18 years at screening. For Japan only: Age &gt;=20 years
             at screening

          -  Patients with chronic HF (Chronic Heart Failure) NYHA (New York Heart Association
             classification) class II-IV and preserved EF (Ejection Fraction)(LVEF (Left
             Ventricular Ejection Fraction) &gt; 40 %) and elevated NT-proBNP (N-terminal of the
             prohormone brain natriuretic peptide) &gt; 300 pg/ml for patients without AF, OR &gt; 900
             pg/ml for patients with AF, analysed at the Central laboratory at Visit 1

          -  Structural heart disease within 6 months prior to Visit 1, OR documented HHF
             (Hospitalisation for Heart Failure) within 12 months prior to Visit 1

          -  Stable dose of oral diuretics, if prescribed

          -  Signed and dated written ICF (informed consent form)

          -  Further inclusion criteria apply

        Exclusion criteria:

          -  Myocardial infarction, coronary artery bypass graft surgery or other major
             cardiovascular surgery, stroke or TIA (Transient Ischaemic Attack) in past 90 days
             prior to Visit 1

          -  Heart transplant recipient or listed for heart transplant

          -  Acute decompensated HF (Heart Failure)

          -  Systolic blood pressure (SBP) &gt;= 180 mmHg at Visit 2.

          -  Symptomatic hypotension and/or a SBP &lt; 100 mmHg

          -  Indication of liver disease,

          -  Impaired renal function, defined as eGFR (Estimated Glomerular Filtration Rate) &lt; 20
             mL/min/1.73 m2 (CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration
             Equation))cr or requiring dialysis

          -  History of ketoacidosis

          -  Treatment with any SGLT (Sodium-glucose co-transporter) -2 inhibitor or combined
             SGLT-1 and 2 inhibitor

          -  Currently enrolled in another investigational device or drug trial

          -  Known allergy or hypersensitivity to empagliflozin or other SGLT-2 inhibitors

          -  Women who are pregnant, nursing, or who plan to become pregnant while in the trial

          -  Further exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alpena</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 24, 2017</lastchanged_date>
  <firstreceived_date>February 16, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
